EMBRACE1: Prostate Biorepository

Caris Science, Inc.1,290 enrolled

Overview

The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for a prostate biopsy. Primarily, results of the Carisome Prostate assay will be compared with pathology results of prostate biopsy procedures. Secondarily, the performance of the Carisome Prostate test will be compared to the current standard of care for the detection of prostate cancer.

Study Type

OBSERVATIONAL

Enrollment

1,290

Conditions

Prostate Cancer

Eligibility

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Men scheduled for a routine prostate biopsy expected to produce a pathology evaluation and report * Blood draw within 7 days prior to scheduled prostate biopsy procedure * Blood draw on the day of but prior to biopsy Exclusion Criteria: * Any previous diagnosis of cancer with the exception of non-melanoma skin cancer * Any prior or ongoing treatment for prostate cancer including prostatectomy or hormone therapy * Prostate biopsy within one month of blood draw * Previous enrollment in the Caris Life Sciences Biorepository

Locations (1)

Caris Science, Inc.

Phoenix, Arizona, United States

Outcomes

Primary Outcomes

Carisome Prostate Assay with prostate biopsy outcome

Association of Carisome Prostate Assay result with prostate biopsy outcome

Time frame: up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.